

Ryan Hohman, VP - Public Affairs, Friends of Cancer Research rhohman@focr.org; 717.333.6248

Friends of Cancer Research Statement on the Proposed House and Senate FDA User Fee Legislation

Washington, DC - May 18, 2022 - Friends of Cancer Research (*Friends*) is encouraged by the notable progress being made within the House and Senate on the upcoming reauthorization of the FDA user fee programs. Representative Pallone and Representative McMorris-Rogers's bill in the House as well as Senator Murray and Senators Burr's newly released legislation in the Senate both support FDA programs to ensure patient safety, lower costs, and spur innovation. These bills are important steps in providing FDA necessary resources to do its work effectively and efficiently.

"Reauthorization of the user fee programs is vital to ensuring that patients receive timely access to the high-quality medical products they deserve," said Jeff Allen, President & CEO, Friends of Cancer Research "This bipartisan effort is critical to advancing many aspects of cancer research and care into the future."

"We applaud the Senate HELP Committee's inclusion of the VALID Act in their user fee package" said Jeff Allen, President & CEO, Friends of Cancer Research "The time is now to modernize the regulatory framework to ensure accuracy and accessibility of diagnostic tests that are the underpinning of so many healthcare decisions."

Today, the House version of H.R. 7667, the "Food and Drug Amendments of 2022" passed unanimously out of the House Energy and Commerce committee, signaling the strong bipartisan support behind the legislation. As the Senate begins their processes toward constructing a final bill, we hope that the priorities within the Senate legislation will proceed with the best interest of patients as a top priority.

We look forward to the continued progress of this important legislation that has the potential to fundamentally improve outcomes for patients across the country.

About Friends of Cancer Research

Friends of Cancer Research (*Friends*) is working to accelerate policy change, support groundbreaking science, and deliver new therapies to patients quickly and safely. We unite scientists, pharmaceutical companies, and policy makers with shared trust and guide them toward meaningful cooperation. This collaboration among partners from every healthcare sector ultimately drives advances in science, policy, and regulation that speed life-saving treatments to patients. For more information, please visit https://friendsofcancerresearch.org/.